静脉环磷酰胺治疗类风湿关节炎相关间质性肺病急性加重:倾向匹配分析
本研究利用日本全国住院数据库回顾性纳入6130例接受高剂量甲泼尼龙治疗的类风湿关节炎相关间质性肺病(RA-ILD)急性加重患者,经1:4倾向评分匹配后比较静脉环磷酰胺(CYC)组(129例)与对照组(516例)。结果显示90天住院死亡率无显著差异(50.4% vs 42.2%,HR 1.20,95%CI 0.91-1.58),但CYC组血小板输注比例更高(7.0% vs 2.3%,OR 3.05,95%CI 1.20-7.73)。
要点
- 静脉CYC作为RA-ILD急性加重初始治疗未显示生存获益。
- CYC组90天住院死亡率50.4%,对照组42.2%,差异无统计学意义。
- CYC组血小板输注比例显著高于对照组(7.0% vs 2.3%)。
核心结论
- 在RA-ILD急性加重患者中,初始静脉CYC治疗未显示生存获益。
- CYC治疗与更高比例的血小板输注相关。
研究设计与样本
- 回顾性观察性研究,使用日本诊断程序组合住院数据库2010年7月至2018年3月数据。
- 纳入入院3天内接受高剂量甲泼尼龙治疗的RA-ILD急性加重患者,共6130例。
- 按入院3天内是否接受静脉CYC分为CYC组和对照组,进行1:4倾向评分匹配,匹配后CYC组129例、对照组516例。
主要发现
- 匹配后CYC组90天住院死亡率为50.4%,对照组为42.2%,风险比1.20(95%CI 0.91-1.58),无显著差异。
- CYC组血小板输注比例为7.0%,对照组为2.3%,比值比3.05(95%CI 1.20-7.73)。
临床怎么用
- 对于RA-ILD急性加重且接受高剂量甲泼尼龙治疗的患者,初始加用静脉CYC需权衡其缺乏生存获益及血小板输注风险增加的可能性。
局限性
- 回顾性数据库研究,存在未测量混杂可能。
- RA-ILD定义基于ICD-10编码,可能存在误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to investigate the effect of intravenous cyclophosphamide (CYC) as the initial therapy in patients with acute exacerbation of rheumatoid arthritis-related interstitial lung disease. METHODS: This was a retrospective observational study. Using the Japanese Diagnosis Procedure Combination inpatient database from July 2010 to March 2018, we identified patients with acute exacerbation of rheumatoid arthritis-related interstitial lung disease (RA-ILD) who received high-dose methylprednisolone within 3 days after admission. RA-ILD was defined as having either the diagnosis of RA-ILD or the diagnoses of both RA and ILD, based on the ICD-10 codes recorded by attending physicians. Patients were divided into two groups: those receiving intravenous CYC within 3 days after admission (CYC group) and those who did not (control group). One-to-four propensity-score matching analyses were performed. RESULTS: A total of 6130 eligible patients were included. After propensity score matching, 129 patients in the CYC group and 516 patients in the control group were further analyzed. 90-day in-hospital mortality, defined as all-cause mortality during hospitalization within 90 days after admission, was not significantly different between the CYC and control groups (50.4% versus 42.2%, hazard ratio 1.20, 95% confidence interval 0.91-1.58). A larger proportion of patients in the CYC group received platelet transfusion than that in the control group (7.0% versus 2.3%, odds ratio 3.05, 95% confidence interval 1.20-7.73). CONCLUSION: In this retrospective database study, the initial therapy with CYC did not show a survival benefit in patients with acute exacerbation of RA-ILD. CYC was associated with a larger proportion of platelet transfusion.
引用
- Nakamura K, Ohbe H, Ikeda K, et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: A propensity-matched analysis using a nationwide inpatient database. Semin Arthritis Rheum. 2021. PMID: 34403813. doi:10.1016/j.semarthrit.2021.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。